Trial Profile
A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Epirubicin (Primary) ; Cyclophosphamide; Docetaxel
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms NATT
- 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 29 Sep 2012 Primary endpoint 'Complete-pathological-response-rate' has not been met.
- 10 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.